

Review

A gluten free diet in the management of epilepsy in people with coeliac disease or gluten sensitivity

Zoë Gilbert ¹ Justine Bold ^{1, 2}

¹ School of Allied Health & Community, University of Worcester, Worcester, WR2 6AJ, UK.

² Centre for Medical Education, Medical School, Cardiff University, Cardiff, CF14 4YS, UK.

* Correspondence: Justine Bold j.bold@worc.ac.uk

Abstract: The aim of this review was to assess the effects of a gluten free diet (GFD) in the management of epilepsy in people with coeliac disease (CD) or gluten sensitivity (GS). A systematic approach was used to undertake a literature review. Five electronic databases (PubMed; Scopus; Google Scholar; Cochrane Epilepsy Group specialised register; Cochrane Register of Controlled Trials (CENTRAL) via the Cochrane Register of Online Trials) were searched using predetermined relevant search terms. 668 articles were identified. Duplicates were removed and predefined inclusion and exclusion criteria were applied, and a PRISMA flow chart was produced. Data was extracted using Covidence software. 12 studies on Epilepsy and CD involving a total of 70 participants were selected for analysis; narrative synthesis was used owing to the small sample sizes in the selected studies. None of the 12 studies meeting inclusion criteria investigated gluten sensitivity and epilepsy. All the included studies support a link between epilepsy and CD. GFD was effective in 45/44 out of 70 participants across the studies in terms of a reduction of seizures, reduction of antiepileptic drugs (AEDs) or normalisation of EEG pattern. A total of 44 participants showed a reduction in seizures (across 8 studies) and complete cessation of seizures was reported in 22 participants. In general, the earlier the GFD is implemented after the onset of seizures, the better the likelihood of the GFD being successful in supporting control of seizures. Mechanisms linking gluten with epilepsy are not fully understood; possible hypotheses include gluten mediated toxicity, immune-induced cortical damage, and malabsorption. Evidence suggests the effectiveness of a GFD in supporting the management of epilepsy in patients with CD, although the quality of evidence is low. There appears to be a growing number of neurologists who are prepared to advocate the use of a GFD. A multidisciplinary approaches and further research are recommended. It could be argued that when balancing potential treatments such as AEDs or surgery, a GFD has a low likelihood of harm.

Keywords:

1. Introduction

1.1 Epilepsy

Epilepsy is a neurological disorder that affects around 70 million people worldwide [1]. It can have a significant effect on the quality of life of those affected and their families [2]. Seizures are usually sudden, acute and unpredictable. People with epilepsy and their cohabiting relatives report higher levels of anxiety, depression and social anxiety disorders compared with the general population [3]. Epilepsy is not one disorder, but a term used to describe several conditions that share seizures as a common element [4]. There are over 40 different types of

seizure [5] and the seizure type and appearance vary depending on which area of the brain is affected. Some people may lose consciousness, collapse and jerk or twitch (tonic-clonic seizure). Other seizures result in a brief loss of consciousness with stiffness, or a complete loss of muscle tone (tonic, atonic, or drop attacks). Absence seizures can cause a person to appear blank and unresponsive for a few seconds. Seizures are classified into two main categories: generalised seizures which affect large areas on both sides of the brain (tonic-clonic, absence, or atonic) and focal seizures that affect a specific region of the brain [6].

In some people the cause is known; brain injury accounts for almost 5% of all seizures [7], but they can also be caused by brain tumour, electrolyte imbalance [8], hormone imbalance or genetic factors [4]. However, in 60% of cases the aetiology is unknown [9] and referred to as 'idiopathic epilepsy' [4]. Lack of sleep [10], stress and anxiety [11], hyperventilation [12] and high caffeine intake can increase seizure susceptibility (although long term low intake can protect from seizures [13]). Epilepsy is primarily controlled pharmacologically, through prescription AEDs, just over half of those taking medication will become seizure free. A further 20-30% will have a reduction in seizures. However, approximately 20% of people continue to suffer seizures despite taking one or more AEDs and this is termed refractory or intractable epilepsy [6].

1.2 Ketogenic diet in management of epilepsy

The ketogenic diet (KD) might improve outcomes in people with epilepsy [14]. The KD has been used for around 100 years in the treatment of refractory epilepsy [15]. The KD is a high-fat, low carbohydrate, adequate protein diet [16]. Mechanisms by which the KD results in improved seizure control are not fully understood. It is thought that the high-fat, restricted carbohydrate intake, results in the production of ketones due to fat metabolism. The anticonvulsant effect of ketones is thought to be due to an upregulation of gene expression involved in energy metabolism in the brain [17]. In the UK, dietary intervention to support epilepsy management is not considered until AEDs have failed to control seizures. In refractory epilepsy, The National Institute for Health and Care Excellence (NICE) guidelines recommend all children, young people and adults be referred to tertiary services offering non-pharmacological interventions and this should involve a multidisciplinary team and include psychological interventions (relaxation, cognitive behaviour therapy, biofeedback); medical intervention (vagus nerve stimulation) or brain surgery [19]. NICE recommends children and young people (but not adults) whose seizures are not controlled by appropriate AEDs should be referred to a paediatric epilepsy specialist for consideration for the use of the KD [18].

Research into understanding the anti-seizure mechanisms of the KD has led some to postulate that the grain free, and therefore the gluten-free nature of the KD, may be a component in its success.

1.3 Gluten and coeliac disease

Gluten is the term used to describe the storage proteins found in wheat, barley and rye[19]. CD is a complex, systemic autoimmune disease triggered by the ingestion of gluten, in genetically susceptible individuals[20]. Worldwide, CD affects approximately 1% of the population[21]. Symptoms associated with CD include diarrhoea, constipation, weight loss and malabsorption[22]. Greater understanding of the pathogenesis of CD in the last few decades has established it can affect any part of the body[23].

The genetic factor associated with CD are the alleles of the human leukocyte antigen (HLA) gene system which is responsible for encoding proteins that regulate the adaptive immune system. The HLA mostly associated with CD is HLA-DQ2 and less commonly, HLA-DQ8[24].

HLA-DQ2 and HLA-DQ8 can bind negatively charged gliadin peptides modified by the enzyme transglutaminase 2 (tTG, TG2). This activates gluten specific (CD4+) T lymphocytes from the mucosa on the lamina propria triggering excretion of proinflammatory cytokines causing mucosal inflammation, atrophy of the small intestine villi and increased gut permeability [25]. The resulting anti-tTG and endomysial antibodies are the main serological marker associated with CD. CD diagnosis must be confirmed by duodenal biopsy [26]. Carrying HLA-DQ2/HLA-DQ8 genes are a key, but not sufficient, component of genetic susceptibility to developing CD [22]. Treatment is lifelong adherence to a strict GFD and although oats are generally considered safe for most people with CD [27]; it appears to cause sensitivity for some people [28] most likely due to contamination with wheat, barley or rye during the production chain [29]. For the majority of individuals with CD after GFD symptoms subside and villi recover [30]. However, despite strict GFD some people with CD experience persistent gastrointestinal (GI) and extraintestinal (EI) symptoms [31].

1.4 Non coeliac gluten sensitivity

Non coeliac gluten sensitivity (NCGS) is a controversial condition [32] and the pathophysiology remains unclear. However, NCGS has been legitimised and three international conferences [33, 34] have provided consensus on the definition of NCGS and the criteria for diagnosis [35, 36]. NCGS appears more common than CD [36, 37] with an estimated prevalence in the general population of 13% [33, 38]. Although GI symptoms are similar to CD there is little or no mucosal damage [24] and the serological markers that are effective in diagnosing CD are not detectable in NCGS [24]. As with CD, removing gluten from the diet results in improvement of symptoms and reintroduction leads to relapse [35].

Neurological dysfunction associated with GS was originally thought to be due to malabsorption, but further research has discovered inflammatory cells in histopathological results of individuals with gluten sensitivity and neurological manifestation and the theory of an innate immune mechanism has emerged [33, 39]. In contrast, CD involves both innate and adaptive immune responses [21].

The EI manifestations of NCGS affect the nervous system, skin and musculoskeletal system [40] and may also include the reproductive system [41]. A number of studies have explored gluten sensitivity with EI manifestations such as tiredness, headache, brain fog [42, 43] and neurological and psychiatric disorders such as ataxia [44], anxiety and depression [45] [46] [47] schizophrenia [48] and epilepsy [49]. For most patients with a neurological manifestation of GS, there are no GI symptoms [50]. Less than 10% of patients with gluten ataxia experience GI symptoms [51]; just over a third will be negative for deaminated-gliadin peptide and tTG2 antibodies [52] but almost three quarters will have circulating antibodies to tissue transglutaminase-6 (TG6) which is primarily associated with the brain [52] and has been associated with CD, epilepsy and cerebral calcifications (CEC) [53].

1.5 Association between epilepsy and coeliac disease

A meta-analysis on epilepsy and systemic autoimmune disorders suggests that people with epilepsy have a 2.6-fold increased risk for CD [54]. In contrast, a large study of people with CD reported a 1.4-fold increased risk of epilepsy [55, 56]. However, this number could be higher given that many people with CD do not have gastrointestinal symptoms [57]. Some studies suggest epilepsy is the most frequent disorder associated with CD [42, 58].

Developments in the understanding of the role of gluten and the gut brain axis [57] has provided a basis for exploring the possibility of supporting epilepsy management through the

GFD. GFD has resulted in a reduction in seizures in some cases [59, 60], particularly those with temporal lobe epilepsy and hippocampal sclerosis [49]. Other case studies have shown complete remission of intestinal and central nervous system manifestations (including electroencephalogram abnormalities associated with seizures) after a GFD, that reappeared after gluten reintroduction [61]. Hence the aim of this review was to assess the effects of a GFD in the management of epilepsy in people with CD or GS. [Strict, lifelong GFD is the cornerstone of treatment for CD.](#)

1.6 Microbiome

Recent evidence from both animal studies and human case studies suggests an imbalance in the microbiome in the gut (known as dysbiosis) may be associated with certain forms of epilepsy [62]. This is an emerging area for research and further work is needed to understand associations; however, it is also recognised that alterations in microbiome may be involved in the immunopathology of CD as there is evidence that gastrointestinal infection and microbiome alterations are associated with the onset or activity of CD [63]. Differences in the composition of the microbiome between patients with CD and patients without it have been reported [64] although no standard CD microbial profile has been identified.

2. Methods

The research strategy was a stand-alone literature review and a systematic approach was used. A systematic review is widely referred to as the ‘gold standard’ review [65]. Literature review also provides a broad overview on many studies to produce a comprehensive picture of that topic which is not possible in a single study [65] and can also be particularly useful to inform and support policy and practice [66]. An ethical checklist was completed, but as it was a review it did not need full ethical approval.

A search was conducted on the International Prospective Register of Systematic Reviews held by the University of York’s Centre for Reviews and Dissemination: PROSPERO [67]. No existing, current, or planned systematic reviews regarding GFD and epilepsy were revealed. An attempt was made to register this review with PROSPERO before the data extraction. Data extraction/analysis in this study was undertaken by a single researcher under supervision, so it did not satisfy the requirements for registering with PROSPERO. This review was however conducted in accordance with the Preferred Reporting Items for Systemic Reviews and Meta-Analyses (PRISMA)[68].

3. Data Collection

Five electronic databases were searched: PubMed, Scopus, Google Scholar, Cochrane Epilepsy Group specialised register and the Cochrane Register of Controlled Trails (CENTRAL) via the Cochrane Register of Online Trials (CRSO). Reference lists from published articles or systematic reviews were hand searched. Covidence software was used for data storage. Boolean operators were used: (Epilepsy/ OR Epileptic/ OR Epileptiform*/ OR Neurological/ OR Seizure/ OR Seizures/ OR Convulsions/ OR Absence/ OR EEG*) AND (Gluten/ OR Gluten-Free/ OR Gliadin Antibodies/ Gluten-free/ OR Transglutaminase/ OR TG6* / OR Coeliac/Celiac) NOT Autism. The review was restricted to intervention studies reporting the effects of GFD on epilepsy or the effect of gluten on seizure activity. To ensure transparency and reduce the risk of bias, predefined inclusion and exclusion criteria were applied.

Table 1. Inclusion criteria.

Location	Worldwide
Language	English
Population	No age restriction, people with a diagnosis of idiopathic epilepsy (irrespective of seizure type); people with seizure disorders and CD with seizure-related neurological abnormalities Animal studies/models investigating gluten and seizure/epileptiform activity EEG
Intervention	Gluten-free diet
Comparisons	No intervention
Setting	No restriction
Outcomes	Any of the following: Reduction in seizures Reduction in medication Reduction in EEG abnormalities Adverse reactions Cognitive or behavioural outcomes Quality of life outcomes
Study design	• RCTs – if available • Cohort studies • Observational studies. • Case Series (Included due to paucity of research)

Exclusion criteria:

- Non-English language papers
- Include participants with other neurological conditions
- Include other known antiepileptic intervention
- Participants with known cause epilepsy
- Non-reporting of compliance to GFD

The following data was collected:

- Participant characteristics: age, sex, number of participants
- Study characteristics: Country, study design, controls, outcomes measured
- Seizure type
- Duration of GFD
- Method of measuring adherence to GFD
- Length of follow up
- Outcome results

Data was extracted prior to quality assessment to reduce risk of bias [67]. Full text papers of all potentially eligible literature were obtained and assessed using the Critical Appraisal Skills Programme (CASP) framework[69]. Data was summarised using tables and narrative synthesis.

4. Results

668 articles were identified (Figure 1) and exported to Covidence. Duplicates were removed; 351 articles remained. Articles were screened (title and abstract), resulting in removal of a further 308. The full-text of 43 articles was read to assess eligibility; inclusion and exclusion criteria were applied. 29 articles were excluded at this stage, with reasons for exclusion detailed in the Supplementary Information. A total of 12 articles were reviewed, all investigating CD and epilepsy in which all participants had biopsy proven CD (see table XX Selected Studies Participant Characteristics, which also provides further details on serological testing if it was undertaken). None of the included studies investigated epilepsy in gluten sensitivity. The selection process has been summarised (Figure 1).


Across the 12 studies reviewed, a GFD was effective in 45/44 out of 70 participants in terms of a reduction of seizures, reduction of AEDs or normalisation of EEG pattern. The earlier the GFD is implemented after the onset, the better the likelihood of the GFD being successful in supporting the control of seizures.

The possible mechanisms involved include, reduced inflammation, resulting in improved gut function which facilitates better absorption of AEDs and nutrients, and reduced gluten induced neurotoxicity. Seizures or EEG abnormalities associated with CD include all seizure types. The association between CD and the distinct syndrome 'CEC' are well established, but CD can be associated with seizures or EEG abnormalities without calcifications or hippocampal sclerosis. GI symptoms are not always present and often the EI manifestation is the only presenting symptom of CD. There was a low risk of adverse effects of the GFD in these studies.

All the included studies support a link between epilepsy and CD [70] [71] [72] [73] [74-76] [77, 78] [79] [80, 81]. Adverse outcomes were reported in 2 studies although this is not necessarily a result of the GFD [70, 72]. Gobbi et al. [70] observed that GFD was more effective in controlling seizures if implemented near the onset of epilepsy, and in childhood.

Gerace et al. [80] using mouse models, demonstrated a correlation between neurotoxicity of proteins associated with gluten: peptide 31-43 and epilepsy. It was shown that the presence of the gliadin peptide 31-43 in the brain, particularly in the hippocampus, where seizures often originate [82], increases the effect of kainate [80]. Kainate suppresses GABA release which is the principal inhibitory neurotransmitter, whilst activating receptors for glutamate; the principal excitatory neurotransmitter in the central nervous system [82]. The researchers hypothesized that transglutaminase activity could mediate the toxic effect of kainate. Hippocampal slices were incubated for 24 hours with peptide 31-43 and it was observed that this significantly increased the expression of TG2/TG6 [80]. As a control, the same experiment was performed using maize zein with no effect.

Volta et al. [73] investigated the presence of anti-neuronal antibodies in adult CD patients with EI symptoms (three with epilepsy), after more, or less prompt, start of a GFD. Anti-neuronal antibodies to CNS were detected in 13 (61%) of the patients with EI symptoms, including two out of the three patients with epilepsy [73]. Compared with only 1 of 20 (5%) of patients without EI manifestations [73]. Furthermore, after GFD, the two out of three patients with epilepsy, who also had CD with GI symptoms, experienced complete cessation of seizures [73]. The third patient with epilepsy, who had CD without GI symptoms, was unaffected by the GFD [73]. The authors report that the anti-neuronal antibodies disappeared in most cases (6 out of 8), within a year of starting the GFD [73].



246

247 **Figure 1:** Prisma flow diagram

4 studies investigated GFD and EEG patterns [72, 77, 78, 83]. The study by Liccheta et al. [74] recorded EEG pattern before the GFD but unfortunately this was not followed up/reported. Berio et al. [83] documented normalisation in 5 out of 6 previously abnormal EEG in patients with good compliance; in contrast with 5 out of 6 patients with poor compliance with GFD who showed abnormal EEG pattern. Five of the included studies document AED use [72, 74, 76, 79, 81]. However, only two studies documented the effect of GFD on AEDs [79, 81].

Arroyo et al. [72] study focused on 24 patients with CEC syndrome, all with calcifications. After GFD, there was no change in calcifications of 10 patients; decreased white-matter density in 7 patients, of which 3 further improved with a marked reduction or disappearance 6-12 months after starting the GFD [72]. Arroyo et al. [72] postulate that the reduction/disappearance of the hypodense areas in the white matter and the stabilising of calcifications, together with improved seizure control relate to improved intestinal absorption. The authors do not clarify whether this relates to improved absorption of nutrients, or AEDs (all patients were on AEDs).

5. Discussion

5.1 Main findings

All authors discussed the potential theories regarding gluten and epilepsy, but only the study by Gerace et al. [80] sought to explore a possible mechanism underlying the relationship between gluten and epilepsy and gluten related diseases, as the purpose of the study. Although the mechanisms underlying the association between CD and epilepsy are not fully understood, three principal hypotheses for potential mechanisms for the association between gluten and epilepsy which have been identified by this study. The hypotheses that emerged are:

1. Gluten mediated toxicity;
2. Gluten involved immune-induced cortical damage; and
3. CD related malabsorption of nutrients.

5.1 Gluten mediated toxicity

Researchers have proposed the theory that gliadin might have a direct toxic effect on the nervous system and specific brain cells [84]. The only study included in this review that explored gliadin toxicity and seizures, was Gerace et al. [80]. The remaining studies acknowledge toxicity as a potential mechanism linking epilepsy with CD. Gliadin toxicity leading to neuronal damage was suggested [81]. Although kainate is not a cause of seizures in human cases, the use of animal models in this way to replicate epilepsy is generally considered highly valid because they closely reproduce the symptoms and biochemical characteristics of the human disease [85]. Some researchers have theorised that antibodies related to CD may be toxic for neurons and trigger the development of epilepsy [59, 86].

5.2 Gluten involved immune-mediated mechanism

Several studies indicated immune-mediated mechanism linking gluten with epilepsy [72, 73, 76, 77, 79, 83]. Research by Pratesi et al. [87] showed antibodies of CD patients with EI symptoms significantly reduced after GFD, yet other studies have not confirmed these findings [88, 89]. The study by Volta, et al. [73] provides support for an autoimmune mechanism linking CD with epilepsy. Autoantibodies TTG, endomysium and antireticulum have reduced with GFD in patients with epilepsy [90-92].

Microbiota and microbiota-derived chemicals, including gut peptides regulate communication between the immune, endocrine, autonomic and enteric nervous systems [93]. Changes in microbiomes were also seen in a small study of short term GFD [94]. Gut microbe dysregulation could contribute to serotonin dysregulation, as serotonin modulates the cortical excitation/inhibition and imbalance may lead to altered seizure threshold [95]. However, due to the highly individualised pattern of intestinal microbiota, the effect of a GFD on gut microbiota cannot be extrapolated from one population to another [96]. Gut microbiome dysbiosis may be involved in the aetiology of epilepsy [97] due to gut microbiota modulation of proinflammatory T-Cell responses, notably cytokine production, leading to epileptogenesis [98].

Gluten in CD causes an adaptive immune response triggering immune cell activation resulting in an increase in proinflammatory cytokines [99]. Increased gut permeability due to this immune response results in increased neuroinflammation and dysfunction of the blood-brain-barrier leaving the brain vulnerable to gliadin and antigliadin antibodies and antineuronal antibodies [100]. Gliadin has been shown to trigger zonulin which modulates not only intestinal permeability but also blood brain barrier permeability [101]. Preliminary animal studies have shown antigliadin antibodies cross react with synapsin which it is proposed could alter seizure threshold, providing a potential mechanism for neurological symptoms [102].

Increased levels of cytokines (interleukin 6) in serum or cerebral spinal fluid have been observed in people with epilepsy [103]. Activation of astrocytes and microglial cells has been linked with major proinflammatory pathways in temporal lobe epilepsy [103]. Studies have demonstrated involvement of chemokines and proinflammatory cytokines in the upregulation of genes associated with immune and inflammatory pathways [104]. Although not fully understood, evidence suggests that gliadin triggers upregulation of neuronal response to nerve stimulation in some people. TG6 linked to gluten ataxia [52] and TG6 antibodies have also been associated with CD, epilepsy and cerebral calcifications [53]. High serum anti-tTG antibodies were observed in participants with epilepsy, demonstrating a general stimulation of both innate and adaptive immune response via T cells due to gluten [75, 81]. Furthermore, autoimmune disorders are often comorbid with epilepsy [105].

5.3 Malabsorption

Malabsorption caused by CD has been proposed as a potential mechanism contributing to the pathogenesis. Specifically, low levels of folic acid, vitamins B12, D and E have been suggested [106]. Hypocalcaemia has been linked with the development of epilepsy [107]. However, some studies have shown that epilepsy can occur without malabsorption [87, 108]. Casciato et al. [76] reported symptoms of vitamin B12 and folate deficiency. Vitamin B12 is important for white matter formation and formation of the myelin sheath. It is hypothesized that if this is compromised it could result in disruption of conductivity of nerves contributing to reduced seizure threshold [71]. Isikay et al. [77] found folic acid levels were lower in a newly diagnosed CD group. The association between low serum and CSF folic acid and CEC was also observed when CD diagnosis is delayed [106]. In a study of 24 patients with CEC, it was suggested that the reduction/disappearance of the hypodense areas in the white matter and the stabilising of calcifications, together with improved seizure control relate to improved intestinal absorption, possibly of folate [72]. Although, as all participants were on AEDs perhaps improved absorption of AEDs might be a factor. Increased serum AEDs were reported by Hernandez et al. [71]. Poor absorption of AEDs has been seen in people with CD [107].

5.4 Timing of commencement of GFD

Studies confirm that prompt implementation of GFD produces improvement/resolution [109, 110]. This is possibly because the longer duration of both conditions might result in irreversible neurological or intestinal damage.

5.5 GFD and AEDs

Hernandez et al. [71] found that GFD improved plasma levels of AEDs. Casciato et al. [76] found a rate of 50% positive response to GFD. AED use was documented in 5 out of the 12 studies included in this review [72, 74, 76] [79, 81]. Only 2 studies investigated the effect of a GFD on AED use, both of the studies reported that after the GFD, AEDs were found to be reduced or discontinued in all of the patients [79, 81]. Several case studies have reported GFD resulted in reduction of AEDs [109].

5.6 EEG

Licchetta et al. [74] observed a wide range of EEG variations consistent with the findings of other studies [90, 111, 112]. Isikay et al. [77] noted a positive correlation between tTG levels and EEG abnormalities in both asleep and awake EEG. This is similar to findings in a study by Emami, et al. [92]. Although the overall sample size across the included studies was small, GFD was associated with varying degrees of favourable reduction in abnormalities in all the included studies [72, 77, 78, 83, 113]. See Table 2. However, hyperexcitability was observed in one participant despite a GFD [81]. EEG pattern is not disease specific [78]. Abnormalities are indicative of potential epilepsy, and although this can be the case, epilepsy is not the only condition suggested by unusual EEG pattern. For example, endocrine disorders can also show similar EEG irregularities [78, 114]. The protocols for EEG recording in the papers included in this review, were not the same, which also limits comparison.

5.7 GFD and multidisciplinary team management

A GFD may result in nutritional deficiencies if poorly implemented and there is evidence that it can be associated with high sugar and low fibre intake if poorly planned [115]. Studies highlight nutrient imbalances when following GFD, particularly in adolescents. GFD can lead to high consumption of lipids and protein and low carbohydrate intake [116], low intake of calcium, fibre and particularly in adolescent girls, low intake of iron [117]. GFD is indicated as a risk factor for metabolic syndrome [117]. It should be noted that no information was provided on the nutritional status of participants in the studies included in this review. Therefore, further studies or research in this area could potentially be improved by consideration of nutritional status. Nutrition professionals are also a useful resource providing information, education, and support for those following a GFD. There is concern regarding self-administration of nutritional supplements and drug interactions for people with epilepsy [118], hence multidisciplinary team working is recommended and interactions need to be checked. It should be noted sodium starch glycolate can contain gluten and can be used as an excipient in AEDs. GFD has a high rate of non-adherence [119]. Studies have shown that when whole families are following the GFD, transgressions are more likely than when only one member of the family is following the GFD [120]. Non-adherence is also higher among teenagers [120].

5.8 Limitations

Overall there is a paucity of data in this area and none of the studies in this review are randomized controlled trials, the included studies are predominantly single centre studies and they treat epilepsy as a single disorder, whereas it is highly heterogeneous. They are also limited by small numbers of participants which limits generalizability [120]. Furthermore, the participants were preselected, having either epilepsy and CD or CD with differing methods used for CD diagnosis with seizures and all but three were without a control population creating further limitations for comparability and generalizability [121]. Additionally, whilst imaging would not be used as a diagnostic test for epilepsy, it may be used to rule out tumours or calcification, imaging was not used in many of the studies. The studies are from five different countries but most ($n=7$) from Italy, which also limits generalisability. Moreover, no standardised GFD protocol exists. Three studies described the method of adherence to GFD [74, 76, 121]. There were differences in length of GFD in each study and methods of measuring adherence. Compliance with GFD is challenging because gluten is present in many food products [79]. Additionally, for people with CD it is generally accepted that GFD must be permanent. Although, some studies have shown that some people with CD can experience symptom resolution despite transgressions from GFD [122]. Strict adherence to the GFD is critical to assessing whether the intervention might work but, studies show that non-compliance is high [123]. All the included studies in this review, implied adherence to GFD but there was a lack of information as to how adherence was assessed. Only 2 of the studies explicitly stated serological or histological testing to assess compliance with GFD [76, 120].

Table 2. Study results summary.

Study	Number of participants on GFD	Method of Measuring Adherence to gluten-free diet	Outcome Seizure Reduction	Outcome AED Reduction	EEG before GFD	EEG after GFD	Adverse Outcome
Arroyo 2002	24	Patients described as compliant with diet in group 3 and implied for other patients Authors comment on patients who had not strictly followed the diet which indicates adherence was monitored	11 patients (45.8%) on AED became seizure free before GFD 9 patients (37.5%) who were on AED became seizure free after introduction of GFD	not documented	15/32 normal	20/32 normal	4 patients on an AED had uncontrolled seizures 3 developed epileptic encephalopathy despite GFD
Bashiri 2016	7	Intestinal biopsy repeated 3 months after starting GFD	6 patients became seizure free 1 patient seizures controlled	AEDs discontinued in 6 patients AED reduced by half in 1 patient	n/a	n/a	None reported
Berio 2015	12	Groups differentiated good/poor compliance	n/a	n/a	not measured	5/6 normal with good compliance to GFD 5/6 abnormal with poor compliance	None reported
Casciato 2015	10	Serological and histological testing	2 patients non-compliant GFD 1 patient lost at follow-up Of the remaining 7 patients: 3 patients became seizure free 3 reduction in number of seizures 1 no change	Not reported	10 abnormal	Not measured	None reported

Gobbi 1992	29 20 followed up	Adherence assumed. Authors state patients were 'prescribed' a GFD	4 patients seizures decreased by more than 50% 6 patients seizure free; 9 patients no change	not reported	4 normal 25 abnormal	Not measured	1 patient increased seizures >50%
Hernandez 1998	4	Monitored and reported Poor compliance noted	Patient 1: seizure frequency decreased by 30% Patient 2: seizure free Patient 3: seizure frequency decreased by 10% Patient 4: seizure frequency decreased by 50%	not reported	4 abnormal	Not measured	None reported
Isikay 2015	132 patients 99 controls	Notes 'effective GFD' for formerly-diagnosed CD patients and 'ineffective GFD' for newly-diagnosed CD patients	n/a	n/a	4 new patients abnormal 9.3% 2 former patients abnormal 1.5% 1 control case abnormal 1%	All normal, including case control which spontaneously normalised	None reported
Liccheta 2011	8	Control visit interviews in the last 12 months to assess compliance	5 patients no clinical benefit 1 patient reduced seizure frequency 1 patient seizure free. 1 not F/U	Not reported	8 abnormal	Not reported	None reported
Parisi 2014	19	Complete adherence confirmed by parents	n/a	n/a	9 abnormal	1 abnormal 1 unknown (parents refused follow-up EEG) 7 normal (77.7%)	None reported

Sel 2017	5	Adherence implied. Reported non-compliance in 1 patient	3 patients stopped AEDs 1 due to stop AED's	3 patients stopped AEDs 1 due to stop AEDs	4 abnormal 1 normal		None reported
Volta 2002	3	Monitored, recorded and reported in paper	2 patients improved, 1 patient not.	n/a	n/a	n/a	None reported

Table 3 Characteristics of participants in studies selected for [review](#)

Study	Mean age (years)	Sex f/m	Mean age at seizure onset (years)	Seizure type	Seizure frequency	EEG	AEDs	Gastrointestinal symptoms	Coeliac Disease
Arroyo 2002	11	22/10	6.13	31 partial 1 generalised tonic-clonic	Most patients: monthly or less 3 patients daily	19 normal 13 abnormal	Yes, all	Absent or rare at time of CD diagnosis but chronic diarrhoea in all cases, appearing at mean age 2.8 years, preceding seizure onset	Yes Biopsy proven
Bashiri 2016	30.2	3/4	16.2	46% generalised tonic-clonic 38% complex partial	3 patients weekly 4 patients monthly	Not measured	Yes, all	No	Yes IgA serum antibodies Biopsy proven
Berio 2013	10-44	Not reported	No seizures	n/a	n/a	5 normal 6 abnormal 1 not measured	n/a	Not reported	Yes anti-tTG serum antibodies and/or biopsy proven

Commented [JB1]: New table moved from supplementary information in response to reviewer comments – to be formatted as table 2

Casciato 2015	31.5	9/1	21.4	6 generalised tonic-clonic 4 partial	2 patients daily 3 patients weekly 5 patients monthly	10 abnormal	Yes, all	yes 3	Yes IgA/IgG-Ttg, IgA/IgG-DGP, & IgA EMA serum antibodies biopsy proven
Gerace 2017	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Gobbi 1992	16.4	28/15	4.5	5 generalised tonic-clonic 24 partial	8 patients >1/day 7 patients >1/week 5 patients >1/month	4 normal 25 abnormal	Not reported	yes 26 no 3	Yes Biopsy proven
Hernandez 1998	18	1/3	7	3 partial 1 generalised tonic-clonic	2 patients > 1/day 1 patient > 1/week 1 patient = 1/week	4 abnormal	Not reported	yes 2 no 2	Yes Biopsy proven
Isikay 2015	10.6	76/56	n/a	n/a	n/a	4 new patients abnormal 9.3% 2 former patients abnormal 1.5% 1 control case abnormal 1%	n/a	yes 121 no 11	Yes Biopsy proven
Liccheta 2011	25.7	7/1	12.85	8 partial	2 >daily 3 daily 2 weekly 1 yearly	8 abnormal	Yes, all	no	Yes Biopsy proven

Parisi 2014	9.82	16/3	No seizures	n/a	n/a	9 abnormal After 6 months GFD EEG abnormalities in 1 patient and 1 patient unknown as parents refused follow-up EEG	n/a	Not reported	Yes Biopsy proven
Sel 2017	6.4	0/4	4.5	2 generalised tonic-clonic 2 partial 1 no seizures (EEG abnormalities only)	not documented	all normalised	4 out of 5	no	Yes Biopsy proven Anti-tTG serum antibodies
Volta 2002	32	3/0	23	1 complex partial temporal lobe 1 simple partial 1 generalised absence	not documented	not measured	not documented	1 yes 2 no	Yes Biopsy proven IgaAGA, IgAEMA, IgA h-tTG serum antibodies

Placebo and nocebo effects of interventions are widely reported in health research [79]. No reference was made to this in the studies included in this review, and therefore it is a factor that affects the reliability. Adherence to existing AED regime was not reported and is therefore a confounding variable and no information about other medications that the participants may be taking. Overall, there is a paucity of research in this field and none of the studies in this review are randomised controlled trials. Consequently, the risk of bias is high and affects the overall quality of evidence available for review.

6. Conclusions

Mechanisms linking gluten with epilepsy are not fully understood but possible hypotheses include gluten mediated toxicity, gluten involved immune-induced cortical damage and CD related malabsorption of dietary nutrients or AEDs. Evidence suggests the effectiveness of a GFD in supporting management of epilepsy [when co-morbid with CD](#), although due to inherent low quality and limitations in methodology, a cautious approach is necessary. There appears to be a growing number of neurologists who are prepared to advocate the use of a GFD; hence multidisciplinary approaches to care are recommended. It could be argued that when balancing potential treatments for epilepsy such as AEDs or surgery with associated side-effects, a [well-planned](#) GFD has a low likelihood of harm. [Papers about GS and epilepsy were not identified for inclusion in this review and therefore findings do not cover the area of GS and epilepsy.](#) Although there is evidence that GS can at times be exclusively a neurological disease and it is established that patients can show neurological symptoms without gut involvement, this review did not identify studies regarding GS and seizures. Hence, [further controlled studies are needed on both GS and epilepsy and CD and epilepsy](#) with tighter protocols concerning education about a GFD before intervention and monitoring compliance with GFD. [It is also recommended that research is undertaken to explore the association between GS and antigliadin antibodies and that there is further investigation of the relationship between tTG levels and epilepsy.](#)

Funding: This project was completed without any external funding.

References

1. Singh, A. and S. Trevick, *The Epidemiology of Global Epilepsy*. Neurologic Clinics, 2016. **34**(4): p. 837-847.
2. Jones, C. and C. Reilly, *Parental anxiety in childhood epilepsy: A systematic review*. Epilepsia, 2016. **57**(4): p. 529-537.
3. Altintas, E., D. Yerdelen, and N. Taskintuna, *Social anxiety level in adult patients with epilepsy and their first-degree cohabiting relatives*. The Journal of Neuropsychiatry and Clinical Neurosciences, 2015. **27**(4): p. 339-344.
4. *What is epilepsy?* Epilepsy Society. 2016.
5. Berg, A., et al., *Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005-2009*. Epilepsia, 2010. **51**(4): p. 676-685.
6. *What is Epilepsy?* Epilepsy Research UK. 2018.
7. Diaz-Arrastia, R., et al., *Posttraumatic epilepsy: The endophenotypes of a human model of epileptogenesis*. Epilepsia, 2009. **50**(s2): p. 14-20.
8. Castilla-Guerra, L., et al., *Electrolytes disturbances and seizures*. Epilepsia, 2006. **47**(2): p. 1990-1998.

9. Fiest, K., et al., *Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies*. Neurology, 2017. **88**(3): p. 296-303.
10. Ferlisi, M. and S. Shorvon, *Seizure precipitants (triggering factors) in patients with epilepsy*. Epilepsy and Behaviour, 2014. **33**(4): p. 101-105.
11. McKee, H. and M.D. Privitera, *Stress as a seizure precipitant: Identification, associated factors and treatment options*. Seizure, 2017. **44**(21): p. 21-26.
12. Chater, S. and K. Simpson, *Effect of passive hyperventilation on seizure duration in patients undergoing ECT*. British Journal of Anaesthesia, 1988. **60**: p. 70-73.
13. van Koert, R.R., et al., *Caffeine and seizures: Asystematic review and quantitative analysis*. Epilepsy and Behaviour, 2018. **80**(3): p. 37-47.
14. Martin, K., K. Jackson, and R. Levy, *Ketogenic diet and other dietary treaments for epilepsy*. 2016, Cochrane Database for Systematic Reviews: 2:CD001903.
15. Neal, E., et al., *The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial*. Lancet Neurology, 2008. **7**(6): p. 500-506.
16. Zhang, Y., et al., *The anticonvulsant effects of ketogenic diet on epileptic seizures and potential mechanisms*. Current Neuropharmacology, 2018. **16**(1): p. 66-70.
17. Bough, K., et al., *Mitochondrial Biogenesis in the Anticonvulsant Mechanism of the Ketogenic Diet*. Annals of Neurology, 2006. **60**(2): p. 223-35.
18. *Epilepsies: diagnosis and management. Clinical Guideline [CG137]: NICE*, in *NICE National Institute for Health and Care Excellence*. 2012.
19. Biesiekierski, J., R, *What is gluten?* Journal of Gastroenterology and hepatology, 2017. **32**(S1): p. 78-81.
20. Husby, S., et al., *European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnoss of coeliac disease*. Journal of Pediatric Gastroenterology and Nutrition, 2012. **54**(1): p. 136-160.
21. Catassi, C., S. Gatti, and A. Fasano, *The new epidemiology of celiac disease*. Journal of Pediatric Gastroenterology and Nutrition, 2014. **59**(S1): p. 7-9.
22. Sollid, L.M., *Coeliac disease: Dissecting a complex inflammatory disorder*. Nature Reviews, 2002. **2**(9): p. 647-655.
23. Fasano, A. and C. C, C, *Clinical Practice. Celiac disease*. New England Journal of Medicine, 2012. **367**(25): p. 2419-2426.
24. Tonutti, E. and Bizzaro, *Diagnosis and classification of celiac disease and gluten sensitivity*. Autoimmunity Reviews, 2014. **13**(4-5): p. 472-476.
25. Leon, A., et al., *The pattern of cytokine expression determines the degree of mucosal damage*. Gut, 2007. **56**(3): p. 441-443.
26. Ludvigsson, J.F., et al., *The Oslo definitions for coeliac disease and related terms*. Gut, 2013. **62**(1): p. 43-52.
27. Garsed, K. and B.B. Scott, *Can oats be taken in a gluten-free diet? A systematic review*. Scandinavian Journal of Gastroenterology, 2007. **42**(2): p. 171-178.
28. Silano, M., et al., *In vitro tests indicate that certain varieties of oats may be harmful to patients with coeliac disease*. Journal of Gastroenterology and Hepatology, 2007. **22**(4): p. 528-531.

- 87 29. Rostami, K., et al., *Gluten-free diet indications, safety, quality, labels and challenges*.
88 Nutrients, 2017. **9**(8): p. 846.
- 89 30. Di Sabatino, A. and C. Catassi, *Clinical Practice. Celiac disease*. New England Journal of
90 Medicine, 2009. **373**(9673): p. 1480-1493.
- 91 31. Abdulkarim, A.S., et al., *Etiology of nonresponsive celiac disease: results of a systematic*
92 *approach*. American Journal of Gastroenterology, 2002. **97**(8): p. 2016-2021.
- 93 32. Spence, D., *Bad medicine: food intolerance*. British Medical Journal (online), 2013.
94 **346**(7893): p. DOI:10.1136/bmj.f529
- 95 33. Catassi, C., et al., *Non-celiac gluten sensitivity: the new frontier of gluten related disorders*.
96 Nutrients, 2013. **5**(10): p. 3839-3853.
- 97 34. Ludvigsson, J.F., et al., *The Oslo definitions for coeliac disease and related terms*. Gut,
98 2013. **62**(1): p. 43-52.
- 99 35. Sapone, A., et al., *Spectrum of gluten-related disorders: consensus on new nomenclature*
100 *and classification*. BMC Medicine, 2012. **10**(13): p. 1-13.
- 101 36. Catassi, C., et al., *Diagnosis of non-celiac gluten sensitivity (NCGS): The Salerno experts'*
102 *criteria*. Nutrients, 2015. **7**(6): p. 4966-4977.
- 103 37. Volta, U., et al., *Study group for non-coeliac gluten sensitivity*. BMC Medicine, 2014.
104 **12**(85): p. doi:10.1186/1741-7015-12-85.
- 105 38. Molina-Infante, J., et al., *Systematic review: Noncoeliac gluten sensitivity*. Alimentary
106 Pharmacology and Therapeutics, 2015. **41**(9): p. 807-820.
- 107 39. Sapone, A., et al., *Differential mucosal IL-17 expression in two gliadin-induced disorders:*
108 *gluten sensitivity and the autoimmune enteropathy celiac disease*. International Archives of
109 Allergy and Immunology, 2010. **152**(1): p. 75-80.
- 110 40. Volta, U., et al., *Non-coeliac gluten/wheat sensitivity: Advances in knowledge and relevant*
111 *questions*. Expert Review Gastroenterology Hepatology, 2017. **11**(1): p. 9-18.
- 112 41. Bold, J. and K. Rostami, *Non-coeliac gluten sensitivity and reproductive disorders*.
113 Gastroenterol Hepatol Bed Bench, 2015. **8**(4): p. 294-297.
- 114 42. Zelnik, N., et al., *Range of neurologic disorders in patients with celiac disease*. Pediatrics,
115 2004. **113**(6): p. 1672-1676.
- 116 43. Harper, L. and J. Bold, *An exploration into the motivation for gluten avoidance in the*
117 *absence of coeliac disease*. Gasterol Hepatol Bed Bench, 2018. **11**(3): p. 259-268.
- 118 44. Hadjivassiliou, M., et al., *Clinical, radiological, neurophysiological and neuropathological*
119 *characteristics of gluten ataxia*. Lancet, 1998. **352**(9140): p. 1582-1585.
- 120 45. Smith, D.F. and L.U. Gerdes, *Meta-analysis on anxiety and depression in adult celiac*
121 *disease*. Acta Psychiatrica Scandinavica, 2012. **125**(3): p. 189-193.
- 122 46. Peters, S.L., et al., *Randomised clinical trial: Gluten may cause depression in subjects with*
123 *non-coeliac gluten sensitivity - An exploratory clinical study*. Alimentary Pharmacology and
124 Therapeutics, 2014. **39**(10): p. 1104-1112.
- 125 47. Busby, E., et al., *Mood disorders and gluten: It's not all in your mind! A systematic review*
126 *with meta-analysis*. Nutrients, 2018. **10**(11): p. 1708-.
- 127 48. Jackson, J., et al., *Neurologic and psychiatric manifestations of celiac disease and gluten*
128 *sensitivity*. Psychiatry Quarterly, 2012. **83**(1): p. 91-102.

- 129 49. Peltola, M., et al., *Hippocampal sclerosis in refractory temporal lobe epilepsy is associated*
130 *with gluten sensitivity*. The Journal of Neurology, Neurosurgery and Psychiatry, 2009.
131 **80**(6): p. 626-630.
- 132 50. Hadjivassiliou, M., et al., *Autoantibodies in gluten ataxia recognize a novel neuronal*
133 *transglutaminase*. Annals of Neurology, 2008. **64**(3): p. 332-343.
- 134 51. Losurdo, G., et al., *Extra-intestinal manifestations of non-celiac gluten sensitivity: An*
135 *expanding paradigm*. World Journal of Gastroenterology, 2018. **24**(14): p. 1521-1530.
- 136 52. Aziz, I. and M. Hadjivassiliou, *Coeliac disease: Noncoeliac gluten sensitivity - food for*
137 *thought*. Nature Reviews. Gastroenterology and Hepatology, 2014. **11**(7): p. 398-399.
- 138 53. Johnson, A.M., et al., *Coeliac disease, epilepsy, and cerebral calcifications: association with*
139 *TG6 autoantibodies*. Developmental Medicine and Child Neurology, 2012. **55**(1).
- 140 54. Lin, Z., Q. Si, and Z. Xiaoyi, *Association between epilepsy and systemic autoimmune*
141 *diseases: a meta-analysis*. Seizure, 2016. **41**(10): p. 160-166.
- 142 55. Ludvigsson, J.F., et al., *Increased risk of epilepsy in biopsy-verified celiac disease: a*
143 *population-based cohort study*. Neurology, 2012. **78**(18): p. 1401-1407.
- 144 56. Rana, A. and A. Musto, *The role of inflammation in the development of epilepsy*. The
145 Journal of Neuroinflammation, 2018: p. 15:144. doi:10.1186/s12974-018-1192-7.
- 146 57. Hadjivassiliou, M., et al., *Gluten sensitivity: from gut to brain*. The Lancet Neurology, 2010.
147 **9**(3): p. 318-330.
- 148 58. Fois, A., et al., *Celiac disease and epilepsy in pediatric patients*. Childs Nervous System,
149 1994. **10**(7): p. 450-454.
- 150 59. Canales, P., et al., *Epilepsy and celiac disease: favourable outcome with a gluten-free diet*
151 *in a patient refractory to antiepileptic drugs*. Neurologist, 2006. **12**(6): p. 318-21.
- 152 60. Hadjivassiliou, M., et al., *Neurological dysfunction in coeliac disease and non-coeliac gluten*
153 *sensitivity*. The American Journal of Gastroenterology, 2016. **9**: p. 561-567.
- 154 61. Berio, A., et al., *Gluten sensitivity and neurological manifestations*. Journal of Biological
155 Research, 2015. **88**(5405): p. 170-172.
- 156 62. Dahlin, M. and S. Prast-Neilsen, *The gut and epilepsy*. EBioMedicine, 2019. **44**: p. 741-746.
- 157 63. Verdu, E., H. Galipeau, and B. Jabri, *Novel players in coeliac disease pathogenesis: role of*
158 *the gut microbiota*. Nat Rev Gastroenterol Hepatol, 2015. **12**: p. 497-506.
- 159 64. Valitutti, F., S. Cucchiara, and A. Fasano, *Celiac disease and the microbiome*. Nutrients,
160 2019. **11**(10): p. 2403.
- 161 65. Gough, D., S. Oliver, and J. Thomas, *Introducing Systematic Reviews*, in *An Introduction to*
162 *Systematic Reviews*., D. Gough, S. Oliver, and J. Thomas, Editors. 2017, Sage Publications
163 Ltd: London. p. 1-17.
- 164 66. Petticrew, M. and H. Roberts, *Systematic Reviews in the Social Sciences: A Practical Guide*.
165 2006, Oxford: Blackwell.
- 166 67. Boland, A., G. Cherry, and R. Dickson, *Doing a systematic review*. 2017, London: Sage.
- 167 68. Liberati, A., et al., *The PRISMA Statement for Reporting Systematic Reviews and Meta-*
168 *Analysis of Studies That Evaluate Health Care Interventions: Explanation and Elaboration*.
169 Annals of International Medicine, 2009. **151**(4): p. 65-94.
- 170 69. *Critical Appraisal Skills Programme (CASP)*. 2017.

70. Gobbi, G., et al., *Coeliac disease, epilepsy, and calcifications. The Italian Working Group on Coeliac Disease and Epilepsy*. Lancet, 1992. **340**(8817): p. 439-443.
71. Hernadez, M.A., G. Colina, and L. Ortigosa, *Epilepsy, cerebral calcifications and clinical or subclinical coeliac disease. Course and follow up with gluten-free diet*. Seizure, 1998. **7**(1): p. 49-54.
72. Arroyo, H.A., et al., *Epilepsy, occipital calcifications, and oligosymptomatic celiac disease in childhood*. Journal of Child Neurology, 2002. **17**: p. 800-806.
73. Volta, U., et al., *Clinical findings and anti-neuronal antibodies in coeliac disease with neurological disorders*. Scandinavian Journal of Gastroenterology, 2002. **37**(11): p. 1276-1281.
74. Licchetta, L., et al., *Epilepsy in coeliac disease: not just a matter of calcifications*. Neurological Science, 2011. **32**(6): p. 1069-1074.
75. Berio, A., et al., *Gluten sensitivity and neurological manifestations*. Journal of Biological Research, 2013. **88**(5405): p. 170-172.
76. Casciato, S., et al., *Cryptogenic focal epilepsy and "hidden" celiac disease in adulthood: a causal or accidental link?* International Journal of Neuroscience, 2015. **125**(12): p. 913-917.
77. Isikay, S., et al., *The frequency of epileptiform discharges in celiac disease*. Pediatric Neurology, 2015. **53**(1): p. 78-82.
78. Parisi, P., et al., *Role of gluten-free diet on neurological-EEG findings and sleep disordered breathing in children with celiac disease*. Seizure, 2015. **25**(doi:10.1016/j.seizure.2014.09.016): p. 181-183.
79. Bashiri, H., et al., *Celiac disease and epilepsy: The effect of gluten-free diet on seizure control*. Advanced Clinical Experimental Medicine, 2016. **25**(4): p. 751-754.
80. Gerace, E., et al., *The gliadin peptide 31-43 exacerbates kainate neurotoxicity in epilepsy models*. Scientific Reports, 2017. **7**(15146): p. 1-10.
81. Sel, C., Genc, et al., *Neurological manifestations of atypical celiac disease in childhood*. Acta Neurologica Belgica, 2017. **117**(3): p. 719-727.
82. Falcon-Moya, R., T.S. Sihra, and A. Rodriguez-Moreno, *Kainate receptors: Role in epilepsy*. Frontiers in Molecular Neuroscience, 2018. **11**(217): p. doi.org/10.3389/fnmol.2018.00217.
83. Berio, A., et al., *Anti-tissue transglutaminase antibodies and EEG pattern in celiac patients on prolonged gluten-free diet*. Journal of Biological Research, 2013. **76**(1): p. 12-15.
84. Giovanni, C., et al., *Induction of apoptosis in caco-2 cells by wheat gliadin peptides*. Toxicology, 2000. **145**(1): p. 63-71.
85. Kandratavicius, L., et al., *Animal models of epilepsy: use and limitations*. Neuropsychiatric Disease and Treatment, 2014. **10**(9): p. 1693-1705.
86. Ludvigsson, J., et al., *Increased risk of epilepsy in biopsy-verified celiac disease: a population-based cohort study*. Neurology, 2012. **78**(18): p. 1401-1407.
87. Pratesi, R., et al., *Serum IgA antibodies from patients with coeliac disease strongly react with human brain blood-vessel structures*. Scandinavian Journal of Gastroenterology, 1998. **33**(8): p. 817-822.

- 212 88. Pellecchia, M.T., et al., *Idiopathic cerebellar ataxia associated with celiac disease: lack of*
 213 *distinctive neurological features*. Journal of Neurology, Neurosurgery and Psychiatry, 1999.
 214 **66**(1): p. 32-35.
- 215 89. Salur, L., et al., *The high frequency of coeliac disease among children with neurological*
 216 *disorders*. European Journal of Neurology, 2002. **7**(6): p. 707-711.
- 217 90. Labate, A., et al., *Silent celiac disease in patients with childhood localization-related*
 218 *epilepsies*. Epilepsia, 2001. **42**(9): p. 1153-1155.
- 219 91. Mavroudi, A., et al., *Successful treatment of epilepsy and celiac disease with a gluten-free*
 220 *diet*. Pediatric Neurology, 2005. **33**(4): p. 292-295.
- 221 92. Emami, M.H., et al., *How frequent is celiac disease among epileptic patients?* Journal of
 222 Gastroenterology and Liver Disease, 2008. **17**(4): p. 379-382.
- 223 93. Geuking, M.B., et al., *The interplay between the gut microbiota and the immune system*.
 224 Gut Microbes, 2014. **5**(3): p. 411-418.
- 225 94. Bonder, M.J., et al., *The influence of a short-term gluten-free diet on the gut microbiome*.
 226 Genome Medicine, 2016. **8**(45).
- 227 95. Epps, S.A. and D. Weinshenker, *Rhythm and blues: Animal models of epilepsy and*
 228 *depression comorbidity*. Biochemical Pharmacology, 2013. **85**(2): p. 135-146.
- 229 96. Garcia-Mazcorro, J.F., G. Noratto, and J.M. Remes-Troche, *The effect of gluten-free diet on*
 230 *health and the gut microbiota cannot be extrapolated from one population to others*.
 231 Nutrients, 2018. **10**(1421): p. 1-14.
- 232 97. Wu, J., et al., *Intestinal Microbiota as an Alternative Therapeutic Target for Epilepsy*.
 233 Canadian Journal of Infectious Diseases and Medical Microbiology, 2016.
- 234 98. Ye, F., et al., *Effect of topiramate on interleukin 6 expression in the hippocampus of*
 235 *amygdala-kindled epileptic rats*. Experimental and Therapeutic Medicine, 2014: p. 223-
 236 227.
- 237 99. Cani, P.D., A. Everard, and T. Duparc, *Gut microbiota, enteroendocrine functions and*
 238 *metabolism*. Current Opinion Pharmacology, 2013. **13**(6): p. 935-940.
- 239 100. Pruimbom, L. and K. de Punder, *The opioid effects of gluten exorphins: asymptomatic*
 240 *celiac disease*. Journal of Health, Population and Nutrition, 2015. **33**(24): p. 1-31.
- 241 101. Fasano, A., *Zonulin and its regulation of intestinal barrier function: the biological door to*
 242 *inflammation, autoimmunity and cancer*. Physiological Reviews, 2011. **91**(1): p. 151-175.
- 243 102. Alaedini, A., et al., *Immune cross-reactivity in celiac disease: Anti-gliadin antibodies bind to*
 244 *neuronal synapsin I*. The Journal of Immunology, 2007. **178**(10): p. 6590-6595.
- 245 103. Aronica, E. and P.B. Crino, *Inflammation in epilepsy: clinical observations*. Epilepsia, 2011.
 246 **52**(s3): p. 26-32.
- 247 104. Aronica, E. and J.A. Gorter, *Gene expression profile in temporal lobe epilepsy*.
 248 Neuroscientist, 2007. **13**(2): p. 100-108.
- 249 105. Amanat, M., et al., *Seizures as a clinical manifestation in somatic autoimmune disorders*.
 250 Seizure, 2018. **12**(doi.org/10.1016/j.seizure.2018.11.012).
- 251 106. Lea, M.E., M. Harbord, and M.R. Sage, *Bilateral occipital calcification associated with celiac*
 252 *disease, folate deficiency, and epilepsy*. American Journal of Neuroradiology, 1995. **16**(7):
 253 p. 1498-1500.

107. Maniar, V., S. Yadav, and Y. Gokhale, *Intractable seizures and metabolic bone disease secondary to celiac disease*. J Assoc Physicians India, 2010. **58**(Aug): p. 512-5.
108. Hadjivassiliou, M., et al., *Does cryptic gluten sensitivity play a part in neurological illness?* Lancet, 1996. **347**(8998): p. 369-371.
109. Molteni, N., et al., *Celiac disease associated with epilepsy and intracranial calcifications: report of two patients*. American Journal of Gastroenterology, 1988. **83**(9): p. 992-994.
110. Sansotta, N., et al., *Celiac disease symptom resolution: Effectiveness of the gluten-free diet*. Journal of Pediatric Gastroenterology and Nutrition, 2018. **66**(1): p. 48-52.
111. Pratesi, R., et al., *Is the prevalence of celiac disease increased among epileptic patients?* Arquivos de Neuro-Psiquiatria, 2003. **61**(2-B): p. 330-334.
112. Lionetti, E., et al., *The neurology of coeliac disease in childhood: What is the evidence? A systematic review and meta-analysis*. Developmental Medicine and Child Neurology, 2010. **52**(8): p. 700-707.
113. Sel, C., et al., *Neurological manifestations of atypical celiac disease in childhood*. Acta Neurologica Belgica, 2017. **117**(3): p. 719-727.
114. Smith, S.J.M., *EEG in neurological conditions other than epilepsy: when does it help, what does it add?* Journal of Neurology, Neurosurgery and Psychiatry, 2005. **76**(s2): p. 8-12.
115. Vincent, A. and P.B. Crino, *Systemic and neurologic autoimmune disorders associated with seizures or epilepsy*. Epilepsia, 2011. **52**(s3): p. 12-17.
116. Vici, G., et al., *Gluten free diet and nutrient deficiencies: A review*. Clinical Nutrition, 2016: p. 1236-1241.
117. Mariani, P., M.G. Viti, and M.e.a. Montuori, *The gluten-free diet: a nutritional risk factor for adolescents with celiac disease?* J Pediatr Gastroenterol Nutr, 1998: p. 519-523.
118. Tortora, R., P. Capone, and G. De Stefano, *Metabolic syndrome in patients with coeliac disease on a gluten-free diet*. Aliment Pharmacol Ther, 2015: p. 352-359.
119. Patsalos, P.N., et al., *The importance of drug interactions in epilepsy therapy*. Epilepsia, 2002. **43**(3): p. 365-385.
120. Khakollari, V., M. Canavari, and M. Osman, *Factors affecting consumers' adherence to gluten-free diet, a systematic review*. Trends in Food Science and Technology, 2019. **85**(1): p. 23-33.
121. Greenhalgh, T., *How to read a paper. The basics of evidence-based medicine. 5th Edition*. 2014, Chichester: John Wiley and Sons.
122. Balakireva, A.V. and J.A. Zamyatin, *Properties of gluten intolerance: Gluten structure, evolution and detoxification properties*. Nutrients, 2016. **8**(10): p. 644-710.
123. Itzlinger, A., F. Branchi, and M. Schumann, *Gluten-free diet in celiac disease - Forever and for all?* Nutrients, 2018. **10**(11): p. 1796-1829.

